Navigation Links
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Date:8/3/2009

BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.

In June, Micromet announced that the company had achieved its primary endpoint in an ongoing Phase 2 study of ALL patients. The company presented data at the the 14(th) Congress of the European Hematology Association (EHA) in Berlin, Germany, showing an 81% response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease (MRD)(1).

The patients included in this phase 2 clinical trial were in complete hematological remission following intense chemotherapy regimens, but retained a detectable level of ALL cancer cells in their bone marrow - so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD.

According to the EMEA, "orphan" medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union, or are medicines which, for economic reasons, would be unlikely to be developed without incentives.

The aim of the EU legislative framework for orphan medicines is to stimulate research and development of medicinal products for rare diseases by providing incentives to the pharmaceutical industry suc
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Announces Pricing of Public Offering of Common Stock
2. Micromet Announces Public Offering of Common Stock
3. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
4. Micromet Added to Russell 3000 Index
5. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
6. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
7. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
8. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
9. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
10. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
11. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Staying true ... to craft a digital product that makes the world ... with Global Biological Standards Institute (GBSI) to redesign their ... clean, and most importantly, strategy-based. , "Biomedical research is ... - much less to promote it in a narrative ...
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that it will release ... on Tuesday, April 28, 2015. United Therapeutics ... 2015, at 9:00 a.m. Eastern Time.  The teleconference is ... A rebroadcast of the teleconference will be available for ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... 18 Danaher Corporation (NYSE: DHR ) announced today ... indirect wholly owned subsidiary, to acquire all of the issued and ... pence per share implying an aggregate price of approximately GBP 50 ... The offer enjoys the recommendation of the Board of Genetix who ...
... , Toronto Stock Exchange Symbol: ... (TSX: MS) today provided the following update on corporate developments: ... -----------------, , The Company has completed its substantive review of ... drug candidate for the treatment of multiple sclerosis (MS). BioMS ...
... , , , , ... stem cell based,technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical,team ... 36 year old Norwegian,patient in a hospital in Beijing. The ... stem cells as well as cancer daughter,cells. The amazing outcome ...
Cached Biology Technology:Danaher Offers to Acquire Genetix Group plc for GBP 50 million pounds Sterling (USD $82 million) 2BioMS Medical provides corporate update 2BioMS Medical provides corporate update 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... office on the Texas A&M University campus, Dr. Marty Dickman,s ... pursuit of scientific excellence that,s what,s fun," Dickman said. ... is to understand what the problems are, how things work ... Dickman paused briefly and with gratitude recently to reflect on ...
... Ten researchers at the University of California, Riverside have ... of Science ( AAAS ). Including this year,s fellows, the ... with AAAS Fellow distinction is 190. Election as a ... peers. This year AAAS gave this honor to 503 of ...
... Iowa State University two of them are also affiliated ... been named fellows of the American Association for the Advancement ... their award citations are: Srinivas ... of Computer Engineering, "For distinguished contributions to high performance computational ...
Cached Biology News:Marty Dickman named AAAS Fellow 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 3AAAS honors Iowa State, Ames Lab researchers for distinguished science 2
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: